LYTIX Stock Overview
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway.
Lytix Biopharma Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr9.50|
|52 Week High||kr21.50|
|52 Week Low||kr9.00|
|1 Month Change||-9.52%|
|3 Month Change||-19.49%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-48.93%|
Recent News & Updates
We're Not Very Worried About Lytix Biopharma's (OB:LYTIX) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
We Think Lytix Biopharma (OB:LYTIX) Can Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|LYTIX||NO Biotechs||NO Market|
Return vs Industry: Insufficient data to determine how LYTIX performed against the Norwegian Biotechs industry.
Return vs Market: Insufficient data to determine how LYTIX performed against the Norwegian Market.
|LYTIX Average Weekly Movement||9.0%|
|Biotechs Industry Average Movement||8.6%|
|Market Average Movement||7.5%|
|10% most volatile stocks in NO Market||12.6%|
|10% least volatile stocks in NO Market||4.3%|
Stable Share Price: LYTIX is not significantly more volatile than the rest of Norwegian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: LYTIX's weekly volatility (9%) has been stable over the past year.
About the Company
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company’s products also include LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase.
Lytix Biopharma Fundamentals Summary
|LYTIX fundamental statistics|
Is LYTIX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LYTIX income statement (TTM)|
|Cost of Revenue||kr0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 25, 2022
|Earnings per share (EPS)||-1.20|
|Net Profit Margin||-756.80%|
How did LYTIX perform over the long term?See historical performance and comparison
Is Lytix Biopharma undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate LYTIX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate LYTIX's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: LYTIX is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: LYTIX is unprofitable, so we can't compare its PE Ratio to the Norwegian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LYTIX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LYTIX is good value based on its PB Ratio (2x) compared to the NO Biotechs industry average (4x).
How is Lytix Biopharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lytix Biopharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Lytix Biopharma performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LYTIX is currently unprofitable.
Growing Profit Margin: LYTIX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LYTIX is unprofitable, but has reduced losses over the past 5 years at a rate of 12.7% per year.
Accelerating Growth: Unable to compare LYTIX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LYTIX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: LYTIX has a negative Return on Equity (-25.34%), as it is currently unprofitable.
How is Lytix Biopharma's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: LYTIX's short term assets (NOK203.0M) exceed its short term liabilities (NOK13.3M).
Long Term Liabilities: LYTIX has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: LYTIX is debt free.
Reducing Debt: LYTIX has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LYTIX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: LYTIX has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 5.2% each year
What is Lytix Biopharma current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LYTIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LYTIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LYTIX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LYTIX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as LYTIX has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Oystein Rekdal, Ph.D. co-founded Lytix Biopharma AS in 2003 and serves as its Chief Executive Officer since September 11, 2019. Dr. Rekdal was Chief Scientific Officer of Lytix Biopharma AS since April...
CEO Compensation Analysis
Compensation vs Market: Oystein's total compensation ($USD747.80K) is above average for companies of similar size in the Norwegian market ($USD331.54K).
Compensation vs Earnings: Oystein's compensation has increased whilst the company is unprofitable.
Experienced Management: LYTIX's management team is considered experienced (3 years average tenure).
Experienced Board: LYTIX's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: LYTIX only recently listed within the past 12 months.
Lytix Biopharma AS's employee growth, exchange listings and data sources
- Name: Lytix Biopharma AS
- Ticker: LYTIX
- Exchange: OB
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: kr380.649m
- Shares outstanding: 40.07m
- Website: https://www.lytixbiopharma.com
Number of Employees
- Lytix Biopharma AS
- Sandakerveien 138
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/18 00:00|
|End of Day Share Price||2022/05/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.